St. Jude Children’s Research Hospital is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

As a cutting-edge research institution, world-class children’s hospital and America’s largest healthcare charity, we are dedicated to one goal: 
The mission of St. Jude Children’s Research Hospital is to advance cures, and means of prevention, for pediatric catastrophic diseases through research and treatment. Consistent with the vision of our founder, Danny Thomas, no child is denied treatment based on race, religion or a family’s ability to pay.

ALSAC – American Lebanese Syrian Associated Charities – is the fundraising and awareness organization for St. Jude. ALSAC is dedicated solely to raising funds and awareness necessary to operate and maintain St. Jude, now, and for the future.
Christian with his mom, Christina brain cancer
Dear Friends of St. Jude,

Our son Christian is a sweet boy who is always looking for ways to help around the house. Whenever his little sister makes a mess, he is the first one with a broom in hand, ready to help clean. Earlier this year, we noticed Christian wasn’t acting like himself. He had trouble using his right arm and was using his left hand for things he normally did with his right.

After repeated trips to the doctor, we received the devastating news that Christian suffered from a rare type of brain cancer called atypical teratoid rhabdoid tumor (ATRT). It was the hardest day of our lives.

Fortunately, we were referred to St. Jude Children’s Research Hospital®, where Christian’s treatment includes proton therapy and chemotherapy. Thanks to St. Jude, our son has a second chance at life.

At St. Jude, not only is Christian receiving exceptional care, but our entire family is also taken care of. If we were anywhere else, it would have been a much more stressful time. Here, we get to focus on Christian’s care and not have to worry about anything else. St. Jude is unbelievable.

Thank you for supporting St. Jude,

Christina and Francisco,
Parents of St. Jude patient Christian
A GREAT CHILDREN’S HOSPITAL

Each year, about 8,500 kids pass through the doors of St. Jude Children’s Research Hospital. They come to St. Jude from all 50 states and from around the world because St. Jude is leading the way the world understands, treats and defeats childhood cancer and other life-threatening diseases.

But being diagnosed with cancer and going to a hospital, many times in a distant city, can be stressful for a child and their family. At St. Jude, we focus on the whole child — their physical and emotional health — as well as the well-being of siblings and the family unit. In fact, St. Jude is often where doctors send their toughest cases, because St. Jude has the world’s best survival rates for some of the most aggressive forms of childhood cancer.

For many of our patients, St. Jude may be their first exposure to needles, medicine and diagnostic equipment, and it can be an intimidating and frightening time. That’s why our compassionate caregivers help children cope with the challenges of hospitalization and treatment by providing age-appropriate explanations and activities to better prepare them for what’s happening. These interactions also build trust so that patients and families know what to expect during this time of change.

As the number of childhood cancer survivors increases, we must consider quality of life not only during treatment but also after treatment ends. A full, rich life is what our patients deserve, and it’s what we strive to give them from the moment they walk through the doors and become part of our St. Jude family.
Treatments invented at St. Jude have helped push the overall childhood cancer survival rate from 20% to more than 80% since we opened more than 50 years ago. We won’t stop until no child dies from cancer.

St. Jude has the largest long-term follow-up clinic for patients.
Abi with her mom, Jamie
bone cancer
In early 2016, hip pain kept Abi from her favorite activities – volleyball and tee ball.

Her mom, Jamie, thought it was growing pains until Abi started having headaches every day. In October, a bone scan and biopsy revealed Abi was suffering from Ewing sarcoma, a type of bone cancer, with tumors in her pelvis, femur, shoulders and skull. A tumor on her lumbar spine fractured a vertebra, leaving her unable to walk.

Abi was immediately referred to St. Jude where treatment included 14 rounds of chemotherapy and 35 rounds of proton therapy. The tumors began to shrink and soon Abi was walking again.

She recently finished treatment and is thriving. On a recent family lake vacation, she jumped from the banks into the water – something her mom wasn’t sure Abi would ever be able to do again.
THE LEADING RESEARCH INSTITUTION

When St. Jude Children’s Research Hospital opened in 1962, a diagnosis of acute lymphoblastic leukemia (ALL), the most common childhood cancer, was all but a death sentence.

Today, through the support of donors and the work of some of the best scientific and medical minds anywhere, kids who come to St. Jude with ALL have a 94 percent chance of survival, the highest anywhere.

Those survival rates are being pushed ever higher thanks to cutting-edge technologies such as the St. Jude Red Frog Events Proton Therapy Center and the St. Jude–Washington University Pediatric Cancer Genome Project, the world’s most ambitious effort yet to discover the origins of childhood cancers and seek new cures.

A new research center is part of a multi-billion dollar expansion, and we are increasing the number of patients being treated on St. Jude-led clinic trials.

What’s more, St. Jude freely shares its groundbreaking discoveries. With the launch of St. Jude Cloud collaborative platform, knowledge and data can be shared more easily and quickly to advance research that could lead to helping even more children around the world suffering from cancer and other life-threatening diseases.
Evidence suggests migratory birds are not a reservoir for highly pathogenic flu viruses

Research led by St. Jude indicates that highly infectious influenza viruses do not persist in wild ducks and other aquatic birds – a finding that offers guidance about how best to combat flu outbreaks on poultry farms.

July 2016 | *Proceedings of the National Academy of Sciences*

CRISPR gene editing reveals new therapeutic approach for blood disorders

A report by an international team of scientists led by St. Jude offers hope that a unique gene editing technique could help overcome certain blood disorders such as sickle cell disease and beta-thalassemia, which can cause lifelong health problems.

August 2016 | *Nature Medicine*

Newly discovered immune cell type protects against lung infections during chemotherapy

A study from St. Jude identifies a new form of an immune cell that provided protection from bacterial pneumonia under conditions that mimicked cancer chemotherapy. The finding points to new ways of strengthening the immune system and protecting cancer patients during chemotherapy.

September 2016 | *Proceedings of the National Academy of Sciences*

Researchers reveal genomic landscape of core-binding factor acute myeloid leukemia

Scientists in the St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project completed a detailed map of the genome of a common form of acute myeloid leukemia in children that makes up about 30 percent of pediatric AML cases.

October 2016 | *Nature Genetics*
Potential targeted therapy found for newly identified leukemia subtype with poor outcome

An international team led by St. Jude identified new details about a high-risk subtype of acute lymphoblastic leukemia (ALL) and identified a drug that shows promise for treating the disease, which is linked to lower survival rates.

November 2016 | Nature Communications

Infant’s prolonged infection reveals mutation that helps bacteria tolerate antibiotics

A life-threatening bacterial infection in an infant fighting leukemia at St. Jude led to an important discovery about antibiotic resistance in this dangerous infection. By sequencing the bacteria’s DNA, researchers linked a single mutation in the bacteria to its ability to survive against antibiotics that effective.

January 2017 | mBio

Research leads to new treatment recommendations for a high-risk pediatric leukemia

In an international study led by St. Jude, researchers identified three genetic missteps that drive acute megakaryoblastic leukemia (AMKL) in children without Down syndrome. The findings have prompted researchers to revise their recommendations for screening and treatment of AMKL.

January 2017 | Nature Genetics

Success of sensory cell regeneration raises hope for hearing restoration

One side effect for some childhood cancer patients is hearing loss due to certain chemotherapy agents that can damage auditory hair cells. St. Jude researchers discovered a way to regenerate auditory hair cells in a laboratory setting. By manipulating genes, researchers induced cells to take on the appearance of immature hair cells and begin producing some of their signature proteins.

April 2017 | Cell Reports
New insights into retinoblastoma revealed in map of cell's genetic controls

New research from the St. Jude Children’s Research Hospital—Washington University Pediatric Genome Project has mapped the intricate changes that occur in the organization of the cell nucleus to determine how cells in the retina of the eye transition from immature to more complex cells, and the timeframe in which some of these cells become cancerous.

May 2017 | Neuron

Discovery of a critical switch in cell development could lead to treatments for cancer

Researchers at St. Jude discovered a switch in the machinery of cells that could open new doors to research and possible treatment of medulloblastoma, the most common malignant brain tumor in children. The research could lead to more precise targeted drug treatments.

June 2017 | Cell Reports

Researchers chart pathway to ‘rejuvenating’ immune cells to fight cancers

St. Jude researchers have identified a mechanism in specialized white blood cells that could explain limited success with a promising immunotherapy. The finding offers a potential new approach for developing more powerful and durable immunotherapies to fight childhood cancer, as well as treatments for viruses such as HIV.

June 2017 | Cell
ST. JUDE FREELY SHARES THE DISCOVERIES WE MAKE

and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.
Pepe is a typical 2-year-old, happy and bubbly and always on the move.

However, in October 2015, he developed a cough that wouldn’t go away. His mother, Tiffany, took him to the emergency room, where he was diagnosed with pneumonia.

Unfortunately, the cough returned and Pepe started having difficulty breathing. A CT scan revealed a mass and Pepe was immediately referred to St. Jude, where he was found to suffer from a cancer called neuroblastoma.

His treatment included chemotherapy and a bone marrow transplant. Today, Pepe is a happy boy who loves to play with his older brother and sister. “Even during treatment, he always has a smile on his face,” said Tiffany. “He’s made us stronger.”
Pepe with his mom, Tiffany cancerous tumor
More than 75% of the costs of St. Jude are covered by generous donors.

1,000,000
One million volunteers support St. Jude

St. Jude has 11 million active donors

Each year 31,000 activities help raise funds and awareness for St. Jude.
AMERICA’S LARGEST HEALTHCARE CHARITY

Every year, millions of generous supporters and volunteers embrace our mission to find cures for children fighting cancer and other life-threatening diseases. They do so through generous donations, small and large, more than 31,000 events each year, including fitness events such as marathons, cycling and walk/run events, as well as with workplace giving, dinner galas and golf tournaments.

That support means the dedicated scientists and doctors at St. Jude have the resources they need to conduct pioneering research to help save children’s lives. It also means a great deal of trust has been shown St. Jude by our supporters and peer organizations who consider us the “highest ranked health non-profit brand” (Harris Poll Equitrend®) and the “number one most inspirational brand” (World Value Index).

That recognition translates into global awareness and ultimately helps ensure that no family will ever receive a bill from St. Jude for treatment, travel, housing or food — because all a family should worry about is helping their child live.

This commitment makes such a critical difference in the lives of the children and families of St. Jude. It means that we can dare to dream as big as St. Jude founder Danny Thomas, who believed we would reach a day when no child dies in the dawn of life.
Mikayla is an artistic girl who loves theater, drawing and singing in the choir.

But, in late 2016, Mikayla was in and out of the doctor’s office in January, and no one could pinpoint just what was wrong. Then, her health worsened and her parents, Kathy and Michael, rushed her to the emergency room where tests revealed Mikayla had a cancerous brain tumor called a medulloblastoma.

After surgery to remove the tumor, Mikayla was referred to St. Jude. Treatment included four rounds of chemotherapy and 30 rounds of proton therapy. Now in fifth grade, Mikayla is a travel buff who loves to read and play games on her tablet.

“St. Jude means everything to us,” Kathy said. “They saved our daughter’s life. The support we had was so comforting.”
Mikayla with her mom, Kathy brain cancer
Kiki
with his father, Raul
brain cancer
A VISION OF THE FUTURE: ST. JUDE GLOBAL

Experts estimate that up to 300,000 children are diagnosed with cancer worldwide each year. The majority of these children live in low- and middle-income countries, where they lack access to adequate diagnosis and treatment. In fact, in many of these countries, it is still 1962, the year Danny Thomas opened the doors of St. Jude and a time when just one in five cancer patients survived into adulthood.

To turn this tide, St. Jude Global is expanding the reach of the world-class treatment and research already available at St. Jude by creating a network of interactive programs and institutions, and forming a global alliance that will improve access to care, enhance the quality of care children receive and provide better options for cures.

Through its focus on three core areas — education, capacity building and research — St. Jude Global aims to grow the number of children whose care it influences from 3 to 30 percent within the next decade. The long-term goal is for all children with cancer to have access to quality care – no matter where they live – so that no child should die in the dawn of life.
Like kids everywhere, David enjoys video games and playing piano and guitar.

Growing up as an American boy in Honduras, he has taken full advantage of his unique experience and learned to speak three languages – English, Spanish and a local dialect of the island where he and his family live.

When David began feeling ill, doctors discovered he had a strain of acute lymphoblastic leukemia called Gamma Delta t-cell ALL. In Honduras, his grandfather, Tom, had to fight through crowds to have David seen by a doctor. Conditions were unsanitary, there was no food and Tom had to sleep on the concrete floor beneath David’s bed for the two nights they were there.

They were referred to St. Jude and, upon arriving, Tom said, “An enormous burden was released.” St. Jude is seeking to unburden families the world over through St. Jude Global, connecting networks of healthcare providers and foundations to improve care for all.

Because it is such a rare strain of ALL, David’s treatment will be more extensive and he’ll undergo nearly three years of chemotherapy. David’s family is extremely grateful for the care he has received at St. Jude. “This is a truly special place,” Tom said. “It is a drop right down from heaven.”
The members of the ALSAC/St. Jude Boards of Directors and Governors are volunteers who serve without compensation. They come from across the country to support the lifesaving work of St. Jude, and many represent the second and third generations of their families to serve on the Boards. An honorary body of emeritus members recognizes the distinguished service on the Boards by those unable to continue to actively participate.

FY17 ALSAC Board of Directors
Officers
Paul J. Ayoub
Partner, Nutter McClennen & Fish LLP
Chair
James B. Barkate
President, Southern Abstracts Inc.
Vice Chair
Frederick R. Harris
Retired
Secretary

FY17 St. Jude Board of Governors
Officers
Martha Perine Beard
Retired
Chair
Camille F. Sarrouf Jr.
Partner, Sarrouf Law LLP
Vice Chair
Susan Mack Aguillard, MD
Pediatrics East
Secretary

FY17 Members
Joyce A. Aboussie
Owner and CEO, Aboussie & Associates
Mahir R. Awdeh, MD
Cardiologist, Cardiology Associates of Memphis
Joseph S. Ayoub Jr.
President, Varuna Strategies LLC
Frederick M. Azar, MD
Chief of Staff, Campbell Clinic
Sheryl A. Bourisk
Partner, BoMin Creative Productions
Robert A. Breit, MD
Radiologist, Smart Scan MRI
Terry L. Burman
Retired
Ann M. Danner
Retired
Joseph M. DeVivo
CEO, InTouch Health
Fred P. Gattas III, PharmD
Nuclear Pharmacist, Triad Isotopes Inc.
Ruth C. Gaviria
Chief Marketing Officer, Entercom Communications
Christopher B. George, MD
Hematologist/Oncologist, Florida Cancer Specialists
Judy A. Habib
President and CEO, KHJ Brand Activation
Gabriel G. Haddad, MD
Physician-in-Chief, Rady Children’s Hospital
Paul K. Hajar
Retired
Charles C. Hajjar
Owner, Hajjar Management Co. Inc.
Fouad M. Hajjar, MD
Hematologist/Oncologist, Children’s Center for Cancer and Blood Diseases
Frederick R. Harris Jr., MD
Gastro One
Bruce B. Hopkins
Chair, West Tennessee Region, First Tennessee Bank
J. David Karam
CEO, Sbarro Inc.
Michael D. McCoy
Sheriff, Peoria County, Illinois
Robert T. Molinet
Global Chief Compliance and Governance Officer, FedEx Corporation
James O. Naifeh Jr.
Team Member, Bernard Health
Ramzi N. Nuwayhid
Private Wealth Advisor, Merrill Lynch Private Banking and Investment Group
Thomas J. Penn, III
President and Owner, Los Angeles Football Club
Joseph C. Shaker
President, Shaker Recruitment Advertising and Communications Inc.
Joseph G. Shaker
Chairman of the Board, Shaker Recruitment Advertising and Communications Inc.
George A. Simon II
Retired
Michael C. Simon
Managing Principal, Traverse Pointe Partners
Paul J. Simon
President, U.S. Group Inc.
Tony Thomas
Partner, Witt/Thomas Productions
Richard M. Unes
Senior Project Manager, Peoria Metro Construction
Paul H. Wein
Partner, LaFave Wein and Frament PLLC
Thomas C. Wertz
Senior Vice President of Wealth Management, UBS Financial Services
Tama H. Zaydon
Executive Director of Investments, Oppenheimer & Company
FY17 Emeritus Members  
(Non-voting members of the Boards)

Thomas G. Abraham  
Chairman of the Board,  
Anthony R. Abraham Foundation

Jack A. Belz  
Chairman and Chief Executive Officer,  
Belz Enterprises

Stephen J. Camer, MD  
General Surgeon,  
New England Baptist Hospital

V. Reo Campian  
Retired

Joseph G. Cory, PhD  
Retired

Leslie S. Dale  
Retired

Lewis R. Donelson III  
Retired

Edward M. Eissey, PhD  
Retired

George Elias Jr.  
Attorney, Law Offices of George Elias Jr.

Hasan M. Elkhatib  
Retired

Fred P. Gattas Jr.  
President, Gattas Company

Sam F. Hamra  
Chairman, Hamra Enterprises

Theodore J. Hazer  
Retired

Richard J. Karam  
Attorney, Law Offices of Richard J. Karam

James A. Kinney  
Retired

Salli E. LeVan  
Retired

Donald G. Mack, MD  
Retired

George M. Maloof  
Retired

Paul J. Marcus  
President, Marcus Capital Management Inc.

James O. Naifeh  
Retired

David B. Nimer  
Independent Import and Export Professional

Talat M. Othman  
President, Grove Financial Inc.

Manal B. Saab  
CEO, Sorrensen Gross Construction Services

Camille F. Sarrouf Sr.  
Partner, Sarrouf Law LLP

Frederick W. Smith  
Chairman, President and CEO,  
FedEx Corporation

Ronald A. Terry  
Retired

Terre Thomas  
Writer

Pat Kerr Tigrett  
President and CEO, Pat Kerr Inc.

Robert P. Younes, MD  
Physician, Conmed Healthcare Management Inc.

Ramzi T. Younis, MD  
Physician, Bascom Palmer Eye Institute

Ex Officio Voting Members

James R. Downing, MD  
President and CEO, St. Jude Children’s Research Hospital

Richard C. Shadyac Jr.  
President and CEO, ALSAC

Chief Governance Officer  
Corporate Secretary

Leah Domitrovic

Epsilon Sigma Alpha  
Representative

Sherry Day  
(Non-elected member)

St. Jude National Outreach Director

Marlo Thomas
The Scientific Advisory Board is an autonomous panel of renowned physicians and scientists who help foster the medical and scientific development of St. Jude, providing guidance and insight on research directions, clinical activities and institutional policy.

**FY17 Chair**
Mignon L. Loh, MD
UCSF Benioff Chair of Children’s Health
Deborah and Arthur Ablin Endowed Chair in Pediatric Molecular Oncology
Professor and Division Chief, Hematology/Oncology
University of California Benioff Children’s Hospital

Patricia A Ganz, MD
Distinguished Professor Health Policy and Management and Medicine
UCLA Fielding School of Public Health
UCLA David Geffen School of Medicine
Director, Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center
University of California at Los Angeles

Michael K. Rosen, PhD
Investigator, Howard Hughes Medical Institute
Mar Nell and F. Andrew Bell Distinguished Chair in Biochemistry
University of Texas Southwestern Medical Center

David P. Harrington, PhD
Professor, Biostatistics
Harvard T.H. Chan School of Public Health
Professor, Biostatistics and Computational Biology
Dana-Farber Cancer Institute

**FY17 Vice Chair**
Theodore S. Lawrence, MD, PhD, FASTRO, FASCO
Isadore Lampe Professor and Chair
Department of Radiation Oncology
University of Michigan Medical School

Ellis J. Neufeld MD, PhD
Egan Family Foundation Professor in Transitional Medicine,
Harvard Medical School
Medical Director,
Boston Hemophilia Center
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Associate Chief, Division of Hematology/Oncology
Boston Children’s Hospital

Jennifer A. Pietenpol, PhD
Benjamin F. Byrd Jr. Endowed Chair in Oncology
Director, Vanderbilt-Ingram Cancer Center
Professor, Biochemistry, Cancer Biology and Otolaryngology
Vanderbilt University School of Medicine
Executive Vice President, Research, Vanderbilt University Medical Center

Raphael E. Pollock, MD, PhD, FACS
Professor and Director, Division of Surgical Oncology
Vice Chairman for Clinical Affairs, Department of Surgery
Surgeon-in-Chief, James Comprehensive Cancer Center
Surgeon-in-Chief, The Ohio State University Health System

Aviv Regev, PhD
Professor, Department of Biology
Massachusetts Institute of Technology
Core Member and Chair of the Faculty
Director, Cell Circuits Program
and Klarman Cell Observatory
Broad Institute
Investigator, Howard Hughes Medical Institute

David H. Rowitch, MD, PhD
Professor and Head of Paediatrics
Wellcome Trust Senior Investigator
Wellcome Trust-MRC Cambridge Stem Cell Institute
Department of Paediatrics
University of Cambridge

Michel W. Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Director, Center for Cell Engineering
Memorial Sloan-Kettering Cancer Center

Joseph W. St. Geme III, MD
Leonard and Madlyn Abramson Professor of Pediatrics and Microbiology
Perelman School of Medicine, University of Pennsylvania
Physician-in-Chief and Chair, Department of Pediatrics
The Children’s Hospital of Philadelphia

Akiko Shimamura, MD, PhD
Associate Professor of Pediatrics
Harvard Medical School
Director, Bone Marrow Failure and Myelodysplastic Syndrome Programs
Dana-Farber Cancer Institute
Boston Children’s Hospital

**FY17 Members**
Daphne A. Haas-Kogan, MD
Professor, Radiation Oncology
Harvard Medical School
Chair, Department of Radiation Oncology
Dana-Farber Cancer Institute

Benjamin F. Cravatt III, PhD
Professor and Chair, Department of Chemical Physiology
The Skaggs Institute for Chemical Biology
The Scripps Research Institute

John Kuriyan, PhD
Investigator, Howard Hughes Medical Institute
Chancellor's Professor
Professor of Molecular Biology and Chemistry
University of California at Berkeley

Raphael E. Pollock, MD, PhD, FACS
Professor and Director, Division of Surgical Oncology
Vice Chairman for Clinical Affairs, Department of Surgery
Surgeon-in-Chief, James Comprehensive Cancer Center
Surgeon-in-Chief, The Ohio State University Health System

Aviv Regev, PhD
Professor, Department of Biology
Massachusetts Institute of Technology
Core Member and Chair of the Faculty
Director, Cell Circuits Program
and Klarman Cell Observatory
Broad Institute
Investigator, Howard Hughes Medical Institute

David H. Rowitch, MD, PhD
Professor and Head of Paediatrics
Wellcome Trust Senior Investigator
Wellcome Trust-MRC Cambridge Stem Cell Institute
Department of Paediatrics
University of Cambridge

Michel W. Sadelain, MD, PhD
Stephen and Barbara Friedman Chair
Director, Center for Cell Engineering
Memorial Sloan-Kettering Cancer Center

Joseph W. St. Geme III, MD
Leonard and Madlyn Abramson Professor of Pediatrics and Microbiology
Perelman School of Medicine, University of Pennsylvania
Physician-in-Chief and Chair, Department of Pediatrics
The Children’s Hospital of Philadelphia

Akiko Shimamura, MD, PhD
Associate Professor of Pediatrics
Harvard Medical School
Director, Bone Marrow Failure and Myelodysplastic Syndrome Programs
Dana-Farber Cancer Institute
Boston Children’s Hospital
FUNDRAISING AND AWARENESS GUIDANCE

The talented and dedicated volunteers who serve on the Professional Advisory Board and the ALSAC Leadership Board are leaders and experts in their fields. They meet regularly to provide guidance to ALSAC on strategic fundraising issues and ways to raise awareness for the St. Jude mission: Finding cures. Saving children.*

FY17 Professional Advisory Board

Jose Barra  
Executive Vice President  
Optum  
Eden Prairie, MN

Marty Belz  
Chairman  
Peabody Hotel Group  
Memphis, TN

Scott Bowman  
Chief Executive Officer  
Global Net Lease  
New York, NY

Douglas (Doug) H. Brooks  
CEO and Chairman (Retired)  
Brinker International  
Plano, TX

Jeb Bush, Jr.  
Chief Operating Officer  
Jeb Bush and Associates, LLC  
Coral Gables, FL

Kay Dempsey  
President and Chief Executive Officer  
The Dempsey Companies  
Atlanta, GA

Christine Duffy  
President  
Carnival Cruise Line  
Miami, FL

Michael Francis  
Founder & CEO  
Farview Associates, LLC  
Orono, MN

Don Germano  
Senior Vice President, Operations  
DICK’S Sporting Goods  
Coraopolis, PA

Rich Hagen  
President, TradeKing Securities, LLC  
CEO, TradeKing Advisors, Inc.  
Charlotte, NC

Mike Hamra  
CEO & President  
Hamra Enterprises  
Springfield, MO

Robert Hureau  
Executive Vice President, Chief Financial Officer  
Pharmaceutical Product Development, Inc.  
Wilmington, NC

Kelle Ilitch  
Co-owner  
Pure Ride  
Birmingham, MI

Alasdair B. James  
President & CEO  
Pier 1 Imports  
Fort Worth, TX

George Joulwan  
General (Retired – U.S. Army)  
Arlington, VA

Kumud Kalia  
Senior Vice President, Chief Information Officer  
Akamai Technologies  
Santa Clara, CA

Jim Karam  
Entrepreneur  
Columbus, OH

Mary Vaughan Lester  
Philanthropist  
Lester California, TX

Anthony (Tony) P. Lewis  
Chairman and CEO  
EOR Energy Services, LLC  
Houston, TX

Michael J. Lynch  
Senior Relationship Manager  
Bank of America Merrill Lynch  
New York, NY

Maguy Maccario-Doyle  
Ambassador  
Embassy of the Principality of Monaco  
Washington DC

T. Allan McArtor  
Chairman and CEO  
Airbus Group, Inc.  
Herndon, VA

Johnny B. Moore, Jr.  
Regional President and CEO  
SunTrust Bank  
Memphis, TN

Marianne Silver  
Chief People Officer, Founder  
Coyote Logistics, LLC  
Chicago, IL

Gary Tobey  
Chairman and CEO  
Haworth Marketing and Media  
Los Angeles, CA

Mark Tritton  
Executive Vice President and Chief Marketing Officer  
Target  
Minneapolis, MN

Eric Trump  
Executive Vice President  
Trump Organization  
New York, NY

LuAnn Via  
Board Director, Advisor  
Strata Sciences, Inc.  
University of Miami, FL

Russell Weiner  
President  
Domino’s USA  
Ann Arbor, MI
Dr. Phil Wenk  
President and CEO  
Delta Dental of Tennessee  
Nashville, TN

Duncan Williams  
President and CEO  
Duncan-Williams, Inc.  
Memphis, TN

Craig Witsoe  
CEO  
Elo Touchscreen Solutions  
Milpitas, CA

FY17 ALSAC Leadership Board

Marilyn Aboussie  
Chief Justice (Retired)  
San Angelo, TX

Amin J. Barakat  
Physician  
Clinical Professor of Pediatrics  
Georgetown University Medical Center  
Washington, DC

Joseph G. (Joe) Bisceglia  
Partner  
Jenner & Block LLP  
Chicago, IL

Pamela Silva Conde  
Journalist/Co-Anchor  
Univision Network  
Miami, FL

Nick Caporella  
Chairman and CEO  
National Beverage Corp.  
Ft. Lauderdale, FL

Terri Carr  
Wisteria Fashions  
Potomac, MD

Robert (Bob) Corliss  
CEO, Robert Talbott, Inc.  
Founding Partner, CorlissMoore  
Monterey, CA

Chaz Corzine  
The MWS Group  
Nashville, TN

Joseph K. DeLapp II  
President and CEO  
Visioneering Technologies, Inc.  
Roswell, GA

Stuart Elias  
American Airlines Manager  
DFW Customer Operations Administration  
DFW Hub Administration  
Flower Mound, TX

Charles A. Feghali  
President  
NGE Systems, LLC  
McLean, VA

Andrew Graves  
Vice President  
JPMorgan Chase Bank, N.A.  
J.P. Morgan Securities, LLC  
New York, NY

Marilena Greig  
Philanthropist and Volunteer  
New Canaan, CT

Trish Coury Gustafson  
Realtor  
Coldwell Banker Previews International  
Newport Beach, CA

Eileen Hutton  
Retired Co-owner, Brilliance Audio  
Hilton Head, SC

Linda Johansen-James  
CEO & President  
International Retail Management and Consulting Group, LLC  
Las Vegas, NV

Lawrence K. Jensen  
President and CEO  
Commercial Advisors, LLC  
Memphis, TN

Albert F. Johary, M.D.  
Physician  
Dunwoody, GA

Rochelle Joseph  
Owner  
Image Consulting and Marketing  
Newburyport, MA

Margo R. Keyes  
Vice Chairman  
Key Development, LLC  
Addison, TX

Wes Kraker  
President and CEO  
Pathmark Transportation  
Memphis, TN

Eunice Mazloom  
Philanthropist and Volunteer  
Arlington, VA

Scott Nietschmann  
Area Director of Operations  
Southern Hospitality Ventures, Inc.  
Lincoln, NE

Kevin Pautler  
Caterpillar, Inc. (Retired)  
The Villages, FL

William C. Perez  
General Counsel  
Pay LLC  
New Orleans, LA

Thomas M. Rashid, M.D.  
St. Francis Hospital, Department of Urology  
Peoria, IL

Andrew San Marco  
Managing Director  
Tradition  
New York, NY

Rick Semonis  
Vice President of Employee Benefits  
J.L. Hubbard Insurance and Bonds  
Peoria, IL

Jack Soden  
CEO  
Elvis Presley Enterprises, Inc.  
Memphis, TN

Gary B. Stone  
President and CEO  
Strategic Thinking One on One  
Houston, TX

John L. Strauss  
President  
The John and Bonnie Strauss Foundation  
Dallas, TX

John Tanner  
Vice Chair  
Prime Policy Group  
Washington, DC
ST. JUDE EXECUTIVE COMMITTEE

James R. Downing, MD
President and Chief Executive Officer

Charles Roberts, MD, PhD
Cancer Center Director
Executive Vice President

Mary Anna Quinn
Chief Administrative Officer
Executive Vice President

James Morgan, PhD
Scientific Director
Executive Vice President

Ellis Neufeld, MD, PhD
Clinical Director
Executive Vice President

Carlos Rodriguez-Galindo, MD
Chair, Global Pediatric Medicine
Executive Vice President

Robyn Diaz, JD
Chief Legal Officer
Senior Vice President

Terrence Geiger, MD, PhD
Deputy Director for Academic and Biomedical Operations
Senior Vice President

Pat Keel
Chief Financial Officer
Senior Vice President

Keith Perry
Chief Information Officer
Senior Vice President

Shari Capers
Vice President, Strategic Planning and Decision Support

Andrew Davidoff, MD
Chair, Surgery

Michael Dyer, PhD
Chair, Developmental Neurobiology

David Ellison, MD, PhD
Chair, Pathology

Amar Gajjar, MD
Chair, Pediatric Medicine

Doug Green PhD
Chair, Immunology

Gerard Grosveld, PhD
Chair, Genetics

Richard Lee, PhD
Interim Chair, Chemical Biology and Therapeutics

Thomas Merchant, DO, PhD
Chair, Radiation Oncology

Zoltan Patay, MD, PhD
Interim Chair, Diagnostic Imaging

Sean Phipps, PhD
Chair, Psychology

Ching-Hon Pui, MD
Chair, Oncology

Mary Relling, PharmD
Chair, Pharmaceutical Sciences

Les Robison, PhD
Chair, Epidemiology

Charles Sherr, MD, PhD
Chair, Tumor Cell Biology

Kumar Srivastava, PhD
Interim Chair, Biostatistics

J. Paul Taylor, MD, PhD
Chair, Cell and Molecular Biology

Elaine Tuomanen, MD
Chair, Infectious Diseases

Mitch Weiss, MD, PhD
Chair, Hematology

Babis Kalodimos, PhD
Chair, Structural Biology

Jinghui Zhang, PhD
Chair, Computational Biology

Stephen Gottschalk, MD
Chair, Bone Marrow Transplant and Cellular Therapy

Suzanne Baker, PhD
Co-Leader, Neurobiology and Brain Tumor Program

Melissa Hudson, MD
Director, Cancer Survivorship Division

Alberto Pappo, MD
Director, Solid Tumor Division
Co-Leader, Developmental Biology and Solid Tumor Program

Charles Mullighan, MBBS, MD
Member, Pathology

Martine Roussel, PhD
Member, Tumor Cell Biology

Victor Santana, MD
Member, Oncology

Jon McCullers, MD, PhD
Chair, Pediatrics at the University of Tennessee Health Science Center (UTHSC)
Pediatrician-in-chief for Le Bonheur Children’s Hospital
ALSAC LEADERSHIP TEAM

Executive Leadership
Richard C. Shadyac Jr.
President and Chief Executive Officer

Emily Callahan
Chief Marketing Officer

Emily S. Greer
Chief Administrative Officer

Sara Hall
Chief Legal Officer

Martin Hand
Chief Donor Officer

Melanee Hannock
Chief Digital and Innovation Officer

Sue Harpole
Chief Development Officer

Robert Machen
Chief Information Officer

Anurag Pandit
Chief Investment Officer

Jeffrey T. Pearson
Chief Financial Officer

George P. Shadroui
Chief Strategy Officer

Steve Froehlich
Deputy Chief Development Officer

Diane Heyman
Human Resources

David Jacques
Information Technology

Betty MacDougall
CEO Operations

Reginald Porter
Enterprise Operations

Mike Siegel
Marketing

Regina Watson
Gift Planning

Vice Presidents
Brenda Abshure
ALSAC Liaison Office and Operations

Amy Lahey
Administrative Operations and Information Security

Evelyn Homs
Multicultural Marketing and Business Development

Kim Humphries
Global Alliances

Lauri Prather
Legal

Kelly Schulz
CEO Operations

Kevin Snyder
Communications

Senior Vice Presidents
Chris Boysen
Field Operations

Wilfred Busby
Enterprise Contact Center

Steve Cox
Marketing and Communications

Steele Ford
Strategic Partnerships

Aimee Hall
Digital
## Combined Financial Highlights for Fiscal Year 2017

### Revenues

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Support</td>
<td>$1,352,732</td>
<td>$1,162,369</td>
</tr>
<tr>
<td>Net Patient Service Revenue</td>
<td>124,099</td>
<td>114,471</td>
</tr>
<tr>
<td>(Insurance Recoveries)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Grants</td>
<td>89,431</td>
<td>88,797</td>
</tr>
<tr>
<td>Net Investment Income</td>
<td>387,143</td>
<td>(2,292)</td>
</tr>
<tr>
<td>Other</td>
<td>18,201</td>
<td>19,886</td>
</tr>
<tr>
<td><strong>Total Revenues</strong></td>
<td><strong>1,971,606</strong></td>
<td><strong>1,383,231</strong></td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Expenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Care Services</td>
<td>427,945</td>
<td>389,040</td>
</tr>
<tr>
<td>Research</td>
<td>368,334</td>
<td>357,419</td>
</tr>
<tr>
<td>Education, Training and Community Support</td>
<td>126,299</td>
<td>96,251</td>
</tr>
<tr>
<td><strong>Total Program Expenses</strong></td>
<td><strong>922,578</strong></td>
<td><strong>842,710</strong></td>
</tr>
<tr>
<td>Fundraising</td>
<td>211,272</td>
<td>202,204</td>
</tr>
<tr>
<td>Administrative and General</td>
<td>143,794</td>
<td>134,681</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>1,277,644</strong></td>
<td><strong>1,179,595</strong></td>
</tr>
</tbody>
</table>

### Gain (loss) on Disposal of Property and Equipment

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>(114)</td>
<td></td>
<td>(963)</td>
</tr>
</tbody>
</table>

### Change in Net Assets

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>702,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Beginning Net Assets

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>3,957,917</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Ending Net Assets

<table>
<thead>
<tr>
<th>Source</th>
<th>2017</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4,659,917</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Christian
with his father, Francisco
brain cancer
“No child should die in the dawn of life.”

That was the belief of our founder, Danny Thomas, and that is at the heart of our mission today. With your continued support, we will never stop looking for the cures that will save the lives of children with cancer and other life-threatening diseases. We will continue to share our research discoveries and provide the very best in patient care.

And families will never receive a bill from St. Jude for treatment, travel, housing or food—because all a family should worry about is helping their child live. Thank you for being a part of this lifesaving work.
To view the 2017 St. Jude Annual Report online, visit stjude.org/financials

Left: St. Jude patient Camila, blood cancer
On the cover: St. Jude patient Javier, mixed germ cell tumor

©2018 ALSAC/St. Jude Children's Research Hospital (33578)